Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
BTLA Polyclonal Antibody
Rabbit Anti Human Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC, IF |
|---|---|
| Primary Accession | Q7Z6A9 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 32834 Da |
| Gene ID | 151888 |
|---|---|
| Positive Control | WB: Jurkat cell lysate; IHC: human intestine tissue; IF; human instetine tissue |
| Application & Usage | WB: 1-2 µg/ml; IHC: 2.5 µg/ml; IF: 20 µg/ml |
| Other Names | BTLA, CD272 |
| Target/Specificity | BTLA |
| Antibody Form | Liquid |
| Appearance | Colorless liquid |
| Formulation | PBS with 0.09% (W/V) sodium azide. |
| Handling | The antibody solution should be gently mixed before use. |
| Reconstitution & Storage | -20 °C |
| Background Descriptions | |
| Precautions | BTLA Polyclonal Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | BTLA {ECO:0000303|PubMed:12796776, ECO:0000312|HGNC:HGNC:21087} |
|---|---|
| Function | Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:12796776, PubMed:14652006, PubMed:15568026, PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14 (PubMed:19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed:19915044). |
| Cellular Location | Cell membrane; Single-pass type I membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The B- and T-lymphocyte attenuator (BTLA) protein is a member of the immunoglobulin superfamily containing a single immunoglobulin (Ig) domain. Like other coihibitory receptors such as CTLA-4 and PD-1, BTLA functions as a receptor that relays inhibitory signals to suppress the immune response, and can inhibit LPS-induced endotoxic shock by suppressing TLR4 signaling in innate immune cells. Polymorphisms in this gene have also been associated with an increased risk of rheumatoid arthritis
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
